Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Kedudukan dalam Saham #24454
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Harga Saham
$0.78611575
Modal Pasaran
$60.45M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-12.06%
Negara
NO
Perdagangan Lytix Biopharma AS (LYTIX)

Kategori

Sejarah hasil dividen untuk Lytix Biopharma AS (LYTIX)
Hasil dividen (TTM) bagi Lytix Biopharma AS (simbol saham: LYTIX) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Lytix Biopharma AS (LYTIX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH